The epidermal growth factor receptor (EGFR, PDB ID: 4I23) kinase domain is another important target, as EGFR is frequently overexpressed in triple-negative breast cancer, a highly aggressive and difficult-to-treat subtype [19]. This evidence concerns the gene EGFR and triple-negative breast carcinoma.